GreenWay Herbal Products

What GreenWay Herbal Products does

GreenWay Herbal Products, LLC is a privately held, Tennessee-based (Murfreesboro) research-driven company founded in 2016 that develops novel cannabinoid compositions intended for evaluation as regulated pharmaceutical candidates. Its core technology is a proprietary 1-to-1 equimolar composition of cannabidiol (CBD) and cannabidiolic acid (CBDA), protected by U.S. Patent No. 12,496,307 (issued December 16, 2025), two UK patents granted in 2023 (GB 2597163 and GB 2614634), and pending applications in Canada, the EU, Israel, and Thailand. Preclinical research conducted with Middle Tennessee State University's Tennessee Center for Botanical Medicine Research (TCBMR) demonstrated that the equimolar composition exhibited significantly greater activity than CBD alone at suppressing cytokine storm activity in animal models, supporting its potential application in inflammation and autoimmune diseases including rheumatoid arthritis, Crohn's disease, lupus erythematosus, multiple sclerosis, Sjogren's syndrome, Graves' disease, celiac disease, psoriatic disease, scleroderma, and autoimmune hepatitis.

The company operates exclusively as a B2B pharmaceutical development and licensing entity, explicitly stating it is not a consumer wellness brand and does not market dietary supplements. Revenue is intended to be generated through strategic licensing partnerships and pharmaceutical development collaborations with pharmaceutical, biotechnology, and specialty health companies, advancing the IP toward FDA-regulated clinical pathways. The company maintains a small team (1-10 employees) led by CEO Jeff Heeren and holds an exclusive research and licensing agreement with the Guangxi Botanical Garden of Medicinal Plants (GBGMP) in China to extend its botanical research pipeline.

Go-to-market is concentrated on enterprise-level, direct engagement with pharmaceutical and biotech decision-makers through a professional website, newsletter, and investor relations channel. Distribution is global in scope via licensing, although no executed licensing deals are publicly disclosed. Pricing is not publicly disclosed, consistent with the B2B pharmaceutical development model.

Name

GreenWay Herbal Products

Legal name

GreenWay Herbal Products, LLC

Website

https://greenwayherbal.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

GreenWay Herbal Products is a Tennessee-based, privately held pharmaceutical development company founded in 2016 that licenses a patented 1-to-1 equimolar CBD/CBDA composition for treating inflammation and autoimmune diseases to pharmaceutical, biotechnology, and specialty health partners under FDA oversight.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceutical Development

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)

Keywords

• Cannabinoid pharmaceutical development
• Botanical drug development
• CBD CBDA therapeutics
• Autoimmune disease research
• Pharmaceutical IP licensing

Headquarters

HQ city

Murfreesboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and Strategic Partnerships: The company generates revenue through strategic licensing partnerships with pharmaceutical, biotechnology, and specialty health companies. The patent serves as the foundation for licensing deals and pharmaceutical development under FDA oversight.
2. Pharmaceutical Development: Advancing cannabinoid science toward regulated pharmaceutical pathways and clinical applications. Revenue may be generated through development partnerships, co-development agreements, or eventual pharmaceutical commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

GreenWay Herbal Products is a research-driven pharmaceutical development company that has discovered, patented, and is developing a proprietary 1-to-1 equimolar composition of cannabidiol (CBD) and cannabidiolic acid (CBDA) intended for evaluation as a regulated pharmaceutical candidate for treating inflammation and autoimmune diseases. The company licenses this intellectual property to pharmaceutical, biotechnology, and specialty health companies rather than selling consumer products.

Product overview

GreenWay Herbal Products, LLC is a research-driven botanical research and product development company focused on evidence-based innovations in cannabinoid science. The company's primary product is its patented 1-to-1 equimolar composition of Cannabidiol (CBD) and Cannabidiolic Acid (CBDA), which originated from university research collaboration with Middle Tennessee State University. The company is advancing this proprietary formulation toward regulated pharmaceutical development under FDA oversight, with the intent to pursue strategic licensing partnerships with pharmaceutical, biotechnology, and specialty health companies. GreenWay is not a consumer wellness brand and does not market dietary supplements as its core business.

Differentiator

Problem solved

Functional benefit

Products and services

• 1-to-1 Equimolar CBD/CBDA Cannabinoid Composition A patented 1-to-1 equimolar composition of Cannabidiol (CBD) and Cannabidiolic Acid (CBDA) intended for evaluation as a regulated pharmaceutical candidate for treating inflammation and autoimmune diseases. Preclinical research demonstrated significantly greater activity than CBD alone at suppressing cytokine storm activity in animal models. Offered to pharmaceutical, biotechnology, and specialty health companies through strategic licensing partnerships under FDA oversight.

Quantifiable outcome

• Significantly greater activity than CBD alone at suppressing cytokine storm activity in animal models

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Middle Tennessee State University (MTSU)coreStrategic or Co-development Partner · 1 January 2016University research collaboration established in 2016 with the Tennessee Center for Botanical Medicine Research (TCBMR). In 2019, research from this collaboration resulted in patent filing by MTSU, later assigned to GreenWay Herbal Products. Preclinical research demonstrated superior activity of the 1-to-1 CBD/CBDA composition at suppressing cytokine storm activity in animal models. TCBMR comprises faculty expertise across biology and chemistry including rapid in vitro cellular screening, compound isolation and purification, and pharmacological evaluation.
• Tennessee Center for Botanical Medicine Research (TCBMR)coreStrategic or Co-development Partner · 1 January 2016Interdisciplinary research center at MTSU established in 2011 to advance discovery and characterization of biologically active plant-derived compounds with pharmaceutical applications. Provides bioassay-guided research approach and pharmacological evaluation capabilities for antibacterial, anticancer, antifungal, antiviral, antiparasitic, and immunomodulatory agents.
• Guangxi Botanical Garden of Medicinal Plants (GBGMP), Nanning, ChinacoreStrategic or Co-development PartnerExclusive research and licensing agreement with the world's largest medicinal plant repository. This collaboration enables access to plant species with documented use in traditional medicine that have not yet been systematically evaluated in Western pharmaceutical research frameworks.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Corbus Pharmaceuticals: Develops cannabinoid-based therapeutics (historically lenabasum) targeting inflammatory and fibrotic diseases. Comparable to GreenWay in pursuing cannabinoid mechanisms for autoimmune and inflammatory indications through FDA-regulated development.
• InMed Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-based therapies (INM-755 for epidermolysis bullosa and others). Directly comparable as a small-cap cannabinoid pharmaceutical developer pursuing rare/specialty disease indications.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Developer of Epidiolex (cannabidiol) for seizure disorders; the most prominent pharmaceutical-grade cannabinoid drug company. Directly comparable to GreenWay as a cannabinoid-composition developer pursuing FDA-regulated pharmaceutical pathways, but at vastly greater scale and with an approved product.
• Botanix Pharmaceuticals: Clinical-stage cannabinoid pharmaceutical developer advancing synthetic CBD for inflammatory skin conditions (e.g., rosacea, atopic dermatitis). Closest analog to GreenWay's preclinical anti-inflammatory positioning with a similar composition-of-matter approach.
• Tetra Bio-Pharma: Canadian cannabinoid-derived drug developer focused on inflammatory and chronic pain indications. Comparable to GreenWay in pursuing FDA-regulated pharmaceutical development of cannabinoid compositions for therapeutic use.

Emerging players

• Emerald Bioscience: Clinical-stage biopharmaceutical developing cannabinoid-based therapeutics for metabolic and inflammatory conditions. Comparable to GreenWay as an emerging player in cannabinoid pharmaceutical development.
• Cardiol Therapeutics: Clinical-stage developer of pharmaceutical CBD formulations for inflammatory heart disease. Comparable as an emerging cannabinoid pharmaceutical company pursuing regulated drug pathways.
• Sirona Biochem: Biotechnology company developing cannabinoid-derived therapeutics and stabilization technology for cannabinoid compounds. Adjacent comparable as a small-cap firm pursuing pharmaceutical-grade cannabinoid science.

Broad incumbents

• Jazz Pharmaceuticals: Global specialty pharmaceutical company that acquired GW Pharmaceuticals and now markets Epidiolex. Relevant incumbent that defines the regulatory and commercial benchmark any cannabinoid pharmaceutical developer must clear.
• Tilray Brands: Large, publicly traded cannabis company with pharmaceutical-grade operations and cannabinoid drug development capabilities. Relevant broad incumbent with overlapping cannabinoid-pharmaceutical interests and significantly greater resources than GreenWay.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/greenway-herbal-products-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GreenWay Herbal Products